HC Wainwright Begins Coverage on Emergent BioSolutions (NYSE:EBS)

Research analysts at HC Wainwright initiated coverage on shares of Emergent BioSolutions (NYSE:EBS) in a report issued on Monday, Marketbeat reports. The firm set a “buy” rating and a $15.00 price target on the biopharmaceutical company’s stock. HC Wainwright’s price objective would indicate a potential upside of 56.90% from the stock’s previous close.

EBS has been the topic of several other reports. Rodman & Renshaw reaffirmed a “buy” rating and set a $16.00 price objective on shares of Emergent BioSolutions in a research note on Friday, September 13th. Benchmark lifted their price objective on Emergent BioSolutions from $8.00 to $12.00 and gave the company a “buy” rating in a research report on Thursday, November 7th. Finally, StockNews.com cut Emergent BioSolutions from a “buy” rating to a “hold” rating in a report on Saturday.

Emergent BioSolutions Stock Up 3.4 %

Shares of NYSE:EBS opened at $9.56 on Monday. The company has a market capitalization of $518.00 million, a PE ratio of -2.33 and a beta of 1.59. The company has a debt-to-equity ratio of 1.30, a quick ratio of 1.47 and a current ratio of 2.88. The company’s fifty day moving average is $9.20 and its 200-day moving average is $8.93. Emergent BioSolutions has a 52 week low of $1.42 and a 52 week high of $15.10.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. State Street Corp lifted its stake in shares of Emergent BioSolutions by 864.7% during the third quarter. State Street Corp now owns 1,911,327 shares of the biopharmaceutical company’s stock valued at $15,960,000 after acquiring an additional 1,713,200 shares during the period. Oak Hill Advisors LP acquired a new position in Emergent BioSolutions in the third quarter valued at approximately $9,296,000. Millennium Management LLC boosted its stake in Emergent BioSolutions by 5.8% in the second quarter. Millennium Management LLC now owns 946,302 shares of the biopharmaceutical company’s stock valued at $6,454,000 after acquiring an additional 52,144 shares during the last quarter. American Century Companies Inc. raised its position in shares of Emergent BioSolutions by 240.9% during the 2nd quarter. American Century Companies Inc. now owns 881,893 shares of the biopharmaceutical company’s stock valued at $6,015,000 after acquiring an additional 623,201 shares during the last quarter. Finally, Assenagon Asset Management S.A. lifted its stake in shares of Emergent BioSolutions by 74.5% in the 3rd quarter. Assenagon Asset Management S.A. now owns 741,552 shares of the biopharmaceutical company’s stock valued at $6,192,000 after purchasing an additional 316,700 shares during the period. Institutional investors and hedge funds own 78.40% of the company’s stock.

About Emergent BioSolutions

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.